CanSino Biologics said on Aug. 25, 2026 its subsidiary CanSino Shanghai signed a strategic framework agreement with Depushi (Hangzhou) Biotechnology to jointly develop mRNA personalized therapeutic cancer vaccines. The collaboration, leveraging each party’s mRNA vaccine technology and tumor neoantigen discovery and design capabilities, targets global development of therapies for gastrointestinal solid tumors and rare cancers and covers early R&D, clinical translation, regulatory filings and comm

CanSino Biologics said on Aug. 25, 2026 its subsidiary CanSino Shanghai signed a strategic framework agreement with Depushi (Hangzhou) Biotechnology to jointly develop mRNA personalized therapeutic cancer vaccines. The collaboration, leveraging each party’s mRNA vaccine technology and tumor neoantigen discovery and design capabilities, targets global development of therapies for gastrointestinal solid tumors and rare cancers and covers early R&D, clinical translation, regulatory filings and commercialization.